Vaxart gets BARDA nod to begin dosing in 10,000-participant portion of phase 2b Covid-19 clinical trial: South San Francisco, California Saturday, May 17, 2025, 18:00 Hrs [IST] Va ...

Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against ...

In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, W ...

Covid vaccine manufacturer Moderna has completed a new site in the UK, which it says will help prepare the the country ...

Vaxart's oral norovirus vaccine shows promise in mid-stage trials, reducing infections by 30%. Read more here.

Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the appointme ...

An oral vaccine reduced infection risk in a trial where people were deliberately exposed to high doses of norovirus, and ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Vaxart Inc (VXRT) reports significant revenue growth and clinical advancements, despite facing operational hurdles and NASDAQ ...

Q1 2025 Management View Steven Lo, CEO, opened by highlighting the lifting of the stop work order on the 10,000 participant ...

King County Public Health is alerting the public that a Canadian visitor was contagious with measles while traveling through ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced its business update and financial results for the first quarter of ...